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DRUG DELIVERY SYSTEM INVOLVING 
INTERACTION BETWEEN PROTEIN OR 
POLYPEPTIDE AND HYDROPHOBIC 
BIODEGRADABLE POLYMER 
This application is a continuation of application Ser. No. 
07/865,657, ?led Apr. 7, 1992, noW abandoned; Which is a 
continuation of application Ser. No. 07/716,763, ?led Jun. 
19, 1991 (noW abandoned); Which is a continuation of 
application Ser. No. 07/554,427, ?led Jul. 19, 1990 (noW 
abandoned). 
BACKGROUND OF THE INVENTION 
(1) Field of the Invention 
The present invention relates generally to the ?eld of 
biodegradable polymers for the controlled release of bio 
logically active agents therefrom. More particularly, the 
present invention relates to a process for preparing hydro 
phobic biodegradable polymers of controlled siZe in Which 
there is a physical interaction With the protein or polypeptide 
incorporated therein. Such an interaction promotes incorpo 
ration of the protein or polypeptide into the polymer matrix 
and alloWs for protection and controlled release of the 
protein or polypeptide from the polymer. 
(2) Background of the Prior Art 
AWide variety of microencapsulation drug delivery sys 
tems have been developed heretofore for the rate controlled 
release of therapeutic agents or other agents. For instance, 
considerable research has been devoted to incorporating 
therapeutic agents into polyesters such as poly-e 
caprolactone), poly(e-caprolactone-Co-DL-lactic acid), poly 
(DL-lactic acid), poly(DL-lactic acid-Co-glycolic acid) and 
poly(e-caprolactone-Co-glycolic acid) in Which release Was 
diffusion controlled. See, for example, Pitt, C. G., GratZl, M. 
M., Jeffcoat, A. R., ZWeidinger, R., Schindler, A., “Sustained 
Drug Delivery Systems. II. Factors Affecting Release Rates 
from Poly(e-caprolactone) and Related Biodegradable 
Polyesters”,J. Pharm. Sci., 68, 1534 (1979). These systems 
Were fabricated as ?lms and capsules and the results suggest 
that the devices can be prepared to erode after release of the 
drug is essentially complete. Degradation of the polyesters 
has been reported to proceed by random hydrolytic cleavage 
of ester linkages by an autocatalytic process With the rate of 
chain cleavage being in?uenced by chemical and morpho 
logical factors. 
Sustained release systems of antimalarial agents and 
sulfadiaZine in glycolic-lactic acid copolymers have also 
been reported. Wise, D. L., Gesser, J. D., McCormick, G. J., 
“Sustained Release of a Dual Anti-malarial System”, J. 
Pharm. PharmacoL, 31, 201 (1979). Wise, D. L., 
McCormick, G. J ., Willett, G. R, Anderson, L. C., HoWes, J. 
F., J. Pharm. PharmacoL, 30, 686 (1978). Methods reported 
by the foregoing investigators involved dissolving the 
agents in a suitable solvent and either spray drying or casting 
?lms according to usual methods and evaporating the sol 
vent. Various narcotic antagonists and steroids have been 
incorporated in ?lms and implanted in rats (e.g., see 
Woodland, J. H. R., Yolles, S., Blake, D. A., Helrich, M., 
Meyer, F. J., “Long-Acting Delivery Systems for Narcotic 
Antagonists: I”, J. Med. Chem., 16, 897 (1973), JackanicZ, 
T. M., Nash, H. A., Wise, D. L., Gregory, J. B., “Polylactic 
Acid as a Biodegradable Carrier for Contraceptive 
Steroids”, Contraception, 8, 227 (1973). Anderson, L. C., 
Wise, D. L., HoWes J. F., “An Injectable Sustained Release 
Fertility Control System”, Contraception, 13, 375 (1976) 
and incorporated into particles injected subcutaneously 
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[Yolles, S., “Time-Release Depot for Anticancer Drugs: 
Release of Drugs Covalently Bonded to Polymers”, J. 
Parent. Drug Assoc., 32, 188(1978)]. The release of a 
number of anti-tumor agents has been evaluated in implant 
able systems as reported in [Yolles, S., “Time Release Depot 
for Anticancer Drugs: Release of Drugs Covalently Bonded 
to Polymers”, J. Parent. Drug Assoc., 32, 188 (1978)], and 
the antibiotic Mitomycin C has been encapsulated in micro 
spherical carriers of gelatin and administered intravenously 
[Yoshioka, T., Hashida, M., Muranishi, S., and SeZaki, H., 
“Speci?c Delivery of Mitomycin C. to Liver, Spleen and 
Lung: Nano- and Microspherical Carriers of Gelatin”, 
Intern. J. Pharm., 81, 131 (1981)] and the effect of siZe on 
in vivo distribution and the potential for antibiotic targeting 
Was discussed. The siZe distribution of the microspheres 
(i.e., 5 to 30 pm) reported in the last mentioned publication 
Was very broad, especially for intravenous administration. 
Recently the in-vitro release of local anesthetics from poly 
lactic acid spheres prepared by a solvent evaporation process 
has, likeWise, been reported [Wakiyama, N., Kaxuhiko, J., 
Nakano, M., “In?uence of Physicochemical Properties of 
Polylactic Acid on the Characteristics and In Vitro Release 
Patterns of Polylactic Acid Microspheres Containing Local 
Anesthetics”, Chem. Pharm. BulL, 30, 2621 (1982)]. The 
patterns of release from these polylactic acid spheres Were 
characteriZed by the various degrees of degradation of the 
polymer as Well as solubilities of loaded drugs, although no 
attempt Was apparently made to evaluate this parameter. 
Additionally, it is apparent that the solubility of the drug 
played an important role in the rate and extent of release. 
Scanning electron photomicrographs also revealed varying 
degrees of erosion and deformation of the spheres after 
release. 
It Will be seen from the foregoing that While the controlled 
release delivery of pharmaceuticals or other agents from 
heretofore described polymeric systems has been principally 
limited to oral, topical or implantable systems in Which the 
considerations relative to pore siZe and/or cell siZe Within 
the carrier matrix as Well as the overall dimensions of the 
microspheres to be administered along With the rate of 
release and the relative absorption rate from a bioavailability 
standpoint are distinctly different from the evaluation 
parameters involved in the utiliZation of these microsphere 
delivery systems for parenteral, i.e., intravenous, 
intraarterial, intramuscular, subcutaneous, intraocular or 
inhalation administration routes to Which the present inven 
tion is particularly applicable. 
For instance, US. Pat. No. 4,818,542 describes a con 
trolled release drug delivery system comprised of a spherical 
microprocess polymeric netWork of interconnecting chan 
nels. 
Further, the use of proteins and peptides as therapeutic 
agents has been recogniZed and their position Within the 
pharmaceutical armamentarium is groWing due to their 
increasing availability. This availability is primarily due to 
recent advances in genetic engineering and biotechnology. 
Unfortunately, the use of proteinaceous drugs by conven 
tional routes of administration is generally hampered by a 
variety of delivery problems. Nonparenteral routes of 
administration, i.e., oral and percutaneous, are inef?cient 
primarily due to poor absorption of proteinaceous drugs into 
the bloodstream and degradation of such drugs in the 
gastrointestinal tract. Rapid proteolytic inactivation of the 
proteinaceous drug also occurs When the drug is adminis 
tered parenterally thus decreasing its bioavailability. In 
addition, When administered by the parenteral route, the 
host’s immune system is activated thereby potentially set 
ting off a series of undesirable immune reactions. 
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In vieW of the foregoing, considerable effort has been 
devoted to developing alternative systems for parenteral 
delivery of peptides and proteins to obviate the problems 
associated With prior art administration techniques. For 
instance, implantable devices have been cast or molded from 
poly-(hydroxy-ethyl)methacrylate, polyvinyl alcohol, 
ethylene-vinylacetate copolymer (EVA) and silicone elas 
tomer. Macromolecular drugs have been embedded in those 
devices. A typical method of preparation involves suspend 
ing a poWder of a macromolecular drug such as a solid 
protein or peptide in a solution containing the polymer. The 
entire composition is then case or molded into the desired 
siZe and shape either by evaporating the solvent or by 
vulcaniZation. A sustained release of macromolecules from 
these devices has been demonstrated. The simplicity of the 
foregoing prior art method is its primary advantage. 
To avoid the foregoing dif?culties, U.S. Pat. No. 4,741, 
872 discloses a method for preparing biodegradable micro 
spheres having a three-dimensional netWork in Which bio 
logically active macromolecular agents are physically 
entrapped therein. 
A number of other types of protein/polymer systems are 
knoWn in the art. For instance, U.S. Pat. Nos. 3,843,446, 
3,977,941 and 4,601,981 discloses the preparation of enZy 
matically active protein-enZyme complex membrane by 
treating another protein membrane With an aqueous solution 
of an enZyme. The membranes are used to effect enZymatic 
reactions. 
US. Pat. No. 3,972,776 discloses the preparation of 
enZymatically active protein-Whole microbial cell complex 
membranes suitable for effecting enZymatic reactions by 
forming a dispersion containing synthetic or natural protein 
macromolecules and Whole microbial cells, casting a mem 
brane from the dispersion and drying the membrane. The 
membranes may also be formed by electro-codeposition 
from a dispersion containing the macromolecular and cells. 
US. Pat. No. 4,758,342 relates to a hyper?ltration mem 
brane containing a supporting layer and a separation layer. 
US. Pat. Nos. 4,494,944 and 4,557,855 disclose a surface 
active agent comprised of lignin sulfonic acids, and 
optionally, an alkylaryl sulfonic free acid With at least ten 
carbon atoms and eight polypeptides having a molecular 
Weight of about 2,500 to about 15,000. 
US. Pat. Nos. 4,585,787 and 4,591,501 disclose a ?exible 
continuous ?lm Which is comprised of a physical admixture 
of a polypeptide, a plasticiZer and a ?lm-forming ?exible 
polymer, When the ?lm is moistened, the polypeptide exudes 
therefrom. 
US. Pat. No. 4,873,033 relates to a hyper?ltration mem 
brane containing a supporting layer and a separation layer. 
The separation layer consists of a crosslinked monomolecu 
lar ?lm of molecules, the molecules of the separation layer 
in the uncrosslinked state being surfactants or surfactant-like 
lipoids containing at least one hydrophobic chain and at least 
one hydrophilic group. The surfactant-like lipoid molecules 
are spread out under a certain spreading pressure or occupy 
an average space over the surface of an aqueous solution or 
at the interface betWeen an aqueous solution and a liquid 
immersible thereWith. 
US. Pat. No. 4,897,444 relates to an immobiliZed ?uo 
rogenic substrate. The substrate has the structure 
Wherein R1 represents an enZyme-speci?c oligopeptide, R2 
represents a spacer group Which is a methylene 
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carboxyloxy, a methylene carboxamido or a methylene 
sulfonamido group attached to a polymethylene chain Which 
itself has a functional group suitable for coupling With a 
polymer; R3 represents a biologically inert polymer; and R4 
represents a ?uorogenic moiety. 
GB 2 207 050 discloses a composition comprising an 
aqueous solution of a drug and a glucose polymer mixture 
Which includes at least 50% by Weight of glucose polymers 
of DR greater than 12. The composition is introduced into 
the peritoneal cavity. The glucose polymers act as osmotic 
agents during peritoneal dialysis. 
EP 0 354 714 discloses a pharmaceutical composition for 
affecting tissue redistribution of bioactive peptides and 
proteins Which are normally bound to glycoaminoglycans, 
and for mimicking the action of glycoaminoglycans in 
biological interactions. The composition comprises a phar 
maceutically acceptable polymeric compound having mono 
meric units and a molecular Weight betWeen 1,000 and 
20,000 Daltons, Wherein each monomeric unit contains 
betWeen three and about 10 aromatic rings. 
EP 0 187 547 relates to polymeric drugs comprising an 
inert synthetic polymeric carrier covalently attached to loW 
molecular Weight bioactive molecules. Drug delivery is 
someWhat targeted because uptake is restricted to cells 
capable of a substrate selective mechanism knoWn as 
pinocytosis. 
In spite of the numerous teachings of the prior art, the 
prior art drug delivery systems still have some signi?cant 
disadvantages and commercialiZation has been difficult to 
achieve especially With respect to sufficient drug loading, 
reproducibility of product speci?cations and scale-up. 
SUMMARY OF THE INVENTION 
It is, therefore, the object of this invention to provide one 
or more processes for the incorporation of polypeptides and 
proteins into a hydrophobic biodegradable polymer to pro 
vide a stable formulation and to achieve protection and 
controlled release of the polypeptide or protein from the 
polymer in vivo. 
It is another object of the present invention to provide for 
a drug delivery system itself Which alloWs for controlled 
release of the polypeptide or protein from the polymer in 
vivo, Wherein said incorporation, protection and controlled 
release are due to the physical interaction betWeen the 
polypeptide or protein and the hydrophobic biodegradable 
polymer. 
A still further object of the present invention is to provide 
a microspherical drug delivery system Which alloWs target 
ing of drugs or other agents to speci?c host tissues or cells 
via injection or inhalation providing high localiZed 
concentrations, sustained activity, systemic administration 
and treatment, thereby minimiZing undesirable systemic 
effects of toxic drugs administered in the native form. 
These and similar objects, advantages and features are 
accomplished according to the methods and compositions of 
the folloWing description of the present invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a description of the precipitation method of 
preparing the drug delivery system of the present invention. 
FIG. 2 is a description of the microsphere method of 
preparing the drug delivery system of the present invention. 
FIG. 3 is a graph depicting the interaction of salmon 
calcitonin (sCT) With polyglycolic acid, polylactic acid and 
copolymers of glycolide and L-lactide at varying molar 
concentrations of polymer. 
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FIG. 4 is a graph of the size distribution of salmon 
calcitonin and polyglycolic acid microspheres. 
FIG. 5 is a graph of the release of salmon calcitonin from 
polyglycolic acid MW=100,000 and salmon calcitonin 
microspheres prepared by freeZe drying. The targeted drug 
load Was 10%. 
FIG. 6 is a graph of the release of salmon calcitonin from 
a polyglycolic acid-salmon calcitonin precipitate. The tar 
geted drug load Was 10%. 
FIG. 7 is a graph of the serum calcium concentration over 
time of a salmon calcitonin/microsphere drug delivery sys 
tem. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS OF THE INVENTION 
A variety of hydrophobic biodegradable polymers are 
suitable in the drug delivery system of the present invention. 
Such polymers are Well-knoWn to those of ordinary skill in 
this art. Suitable polymers include polyesters, polyorthoe 
sters and polyanhydrides. 
The polymer may comprise copolymeric and homopoly 
meric polyesters containing hydrolyZable inter linkages 
Which are, therefor, biodegradable. Typically preferred of 
such polyesters are polyglycolic (PGA) and polylactic 
(PLA) acids, and copolymers of glycolide and L-lactide 
(PGL). The aforementioned polyesters are particularly 
suited for the methods and compositions of the present 
invention by reason of their characteristically loW human 
toxicity and virtually complete biodegradability. of course, it 
Will be understood that the particular polyester or other 
polymer, oligomer, copolymer, and the like, utiliZed in the 
present invention is not critical and a variety of hydrophobic 
biodegradable polymers may be utiliZed as a consequence of 
the novel processing methods of the invention Which yield 
the desired drug delivery system, irrespective of the source 
of polymer utiliZed. 
Accordingly, other biodegradable or bioerodable poly 
mers or copolymers evidencing the necessary loW degree of 
toxicity suitable for use in the present invention include, for 
example, gelatin, agar, starch, arabinogalactan, albumin, 
collagen, natural and synthetic materials or polymers, such 
as poly(e-caprolactone), poly(e-caprolactone-Co-lactic 
acid), poly(e-caprolactone-Co-glycolic acid), poly([3 
hydroxy butyric acid), polyethylene oxide, polyethylene, 
poly(alkyl-2-cyanoacrylate), (e.g., methyl, ethyl, butyl, and 
the like), hydrogels (e.g., poly(hydroxyethyl methacrylate 
poly-hydroxyethyl methacrylate), polyamides (e.g., 
polyacrylamide), poly(amino acids)(i.e., L-leucine, 
L-aspartic acid, [3-methyl-L-aspartate, [3-benZyl-L-aspartate, 
glutamic acid and the like), poly(2-hydroxyethyl-DL 
aspartamide), poly(ester urea), poly(L-phenylalanine/ 
ethylene glycol/1,6-diisocyanatohexane), poly(methyl 
methacrylate), 3,9-bis methylene-2,4,8,10-tetraoxaspirol 
[5,5] undecane, 1,6-hexadiol polyorthoester, poly(bis-p 
carboxyphenoxypropane anhydride), ethylene-vinylacetate 
copolymer (EVA), polyvinyl alcohol (PVA) and silicone 
elastomer. 
The foregoing exemplary natural and synthetic polymers 
suitable for use in the present invention are, of course, either 
readily available commercially or are obtainable by conden 
sation polymeriZation reactions from the suitable monomers 
or, comonomers or oligomers. For instance, homopolymers 
and copolymers of glycolic and lactic acids can be prepared 
by direct poly-condensation or by reacting glycolide and 
lactide monomers as disclosed by Gilding, D. K., Reed, A. 
M., “Biodegradable Polymers for Use in Surgery— 
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Polyglycolic/Poly(lactic acid) Homo- and Copolymers: 1”, 
Polymer, 20, 1459 (1979). 
Any protein or polypeptide is suitable in the practice of 
the present invention. Biologically active proteins or 
polypeptides for use in the present invention are proteins or 
polypeptides of relatively small molecular Weights. Exem 
plary preferred biologically active polypeptides for use 
herein are calcitonin, insulin, angiotensin, vasopressin, 
desmopressin, LH-RH (luteiniZing hormone-releasing 
hormone), somatostatin, glucagon, somatomedin, oxytocin, 
gastrin, secretin, h-ANP (human atrial natriuretic 
polypeptide), ACTH (adrenocorticotropic hormone), MSH 
(melanocyte stimulating hormone), beta-endorphin, 
muramyl dipeptide, enkephalin, neurotensin, bombesin, VIP, 
CCK-8, PTH (parathyroid hormone), CGRP (calcitonin 
gene related peptide), endothelin, TRH (thyroid releasing 
hormone), groWth hormones like erythropoietin, lymphok 
ines like macrophage stimulating factor, and the like. The 
various polypeptides for use herein include not only the 
naturally occurring polypeptides themselves but also phar 
macologically active derivatives and analogs thereof. Thus, 
for example, calcitonin intended for use in the present 
invention includes not only naturally occurring products 
such as salmon calcitonin, human calcitonin, porcine 
calcitonin, eel calcitonin and chicken calcitonin, but also 
analogs such as [Asu1’7]-eel calcitonin elcatonin, a product 
of Toyo JoZo Company, Ltd., as Well. Similarly, LH-RH for 
use herein includes not only the naturally occurring product 
but also the pharmaceutically active derivatives and analogs 
thereof such as described in various patents and publications 
referenced hereinabove, e.g., MatsuZaWa et al US. Pat. No. 
3,917,825. Especially preferred polypeptides for use in the 
present invention include calcitonin, insulin, ACTH, 
LH-RH, PTH, CGRP, somatostatin and somatomedin. Cal 
citonin is the most preferred. 
Biodegradable synthetic polypeptides include poly-(N 
hydroxyalkyl)-L-asparagine, poly-(N-hydroxy-alkyl)-L 
glutamine, copolymers of N-hydroxyalkyl-L-asparagine and 
N-hydroxyalkyl-L-glutamine With other amino acids. 
De?nitions or further description of any of the foregoing 
terms and phrases are Well knoWn in the art and may be 
found by referring to any standard biochemistry reference 
text such as “Biochemistry” by Albert L. Lehninger, Worth 
Publishers, Inc. and “Biochemistry” by Lubert Stryer, W. H. 
Freeman and Company, both of Which are hereby incorpo 
rated by reference. 
The amount of the biologically active peptide in the drug 
delivery system of the present invention Will vary, depend 
ing upon the particular polypeptide employed, but Will be an 
amount sufficient to elicit the desired pharmacological 
effect. Thus, for example, When the selected polypeptide is 
calcitonin, such Will be present in an amount sufficient to 
treat a condition such as Paget’s disease or hypercalcemia or 
osteoporosis. A typical preparation may contain, for 
example, from about 0.01 to about 0.04 I.U./mg for porcine 
calcitonin. In the case of insulin, an amount sufficient to 
control blood sugar levels and thus to treat diabetes Will 
typically be employed; in the case of LH-RH or analog 
thereof, an amount sufficient to treat diabetes Will typically 
be employed; in the case of LH-RH or analog thereof, an 
amount sufficient to treat various disorders of the female 
reproductive system, an amount sufficient to have a contra 
ceptive effect, or an amount sufficient to elicit any other 
knoWn biological response to LH-RH Will be used, in the 
case of PTH, CGRP, somatomedin or analog thereof, an 
amount sufficient to treat various disorders of bone metabo 
lism Will be used; and so on for the other biologically active 
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peptides contemplated by the present invention. Thus, the 
amount of protein or polypeptide useful in the drug delivery 
system of the present invention is an amount sufficient to 
achieve the desired therapeutic effect. For guidance, refer 
ence may be made to any standard reference text such as 
Goodman and Gilman, The Pharmacological Basis of 
Therapeutics. 
In order to improve the properties and appearance of the 
drug delivery system of the present invention, one or more 
excipients, coloring agents, isotonic agents, antioxidants, 
and the like, may be added to the drug delivery system, for 
example, excipients such as starch, dextrin, mannitol, 
sorbitol, cyclodextrin and tragacanth, coloring agents such 
as beta-carotene, red color No. 2 and blue color No. 1, 
isotonic agents such as sodium chloride and glucose, and 
antioxidants such as ascorbic acid and erythorbic acid and 
their salts or esters. Actual methods of preparing such 
dosage forms are knoWn or Will be apparent, to those skilled 
in the art. For example, see Remington’s Pharmaceutical 
Sciences, 17th edition, 1985, ed. Alfonso R. Gennaro, Mack 
Publishing Company, Easton, Pa. 18042. 
The nature of the excipient(s) Will preferably aid in the 
manufacture of the dosage form selected. Certain dosage 
forms provide a more extended release of the biologically 
active protein or polypeptide. These extended release dosage 
forms are particularly useful and offer increased ?exibility in 
the administration of the protein or polypeptide. 
An important feature of the present invention is the fact 
that there is a physical interaction betWeen the hydrophobic 
biodegradable polymer and the protein or polypeptide of the 
present invention. That physical interaction may be charac 
teriZed as an af?nity or as some type of association or 
interaction betWeen the polymer and the protein/ 
polypeptide. 
The physical interaction or adsorption is not clearly 
understood but it may be characteriZed someWhat by What it 
is not. The interaction does not appear to be chemical in 
nature, i.e., it is not a covalent bond, hydrogen bond or the 
like. This deduction is on the basis of Differential Scanning 
Calorimetry, Infrared Spectroscopy, Fourier Transform 
Infrared Spectroscopy, Raman Spectroscopy and Fourier 
Transform Raman Spectroscopy. While not Wishing to be 
bound by any theory, the present inventor believes that the 
-interaction is hydrophobic in nature and involves the amino 
acid chain linkages. Brie?y, it may be depicted as an 
equilibrium mechanism: 
Calcitonin+PolymerSCalcitonin-Polymer 
Such a mechanism Would alloW for incorporation of the 
protein or polypeptide into the polymer matrix as Well as 
alloWing its release from the matrix When localiZed in a body 
compartment in Which the released protein or polypeptide 
diffuses from the site. 
The drug delivery system of the present invention may be 
prepared by any procedure Which alloWs for the formation of 
a physical interaction betWeen the hydrophobic biodegrad 
able polymer and the protein or polypeptide. TWo such 
processes may be referred to as the polymer precipitation 
technique or the microsphere technique. 
In the polymer precipitation technique, the polypeptide 
and polymer are mixed together With a suitable solvent to 
form a homogeneous liquid state as depicted in FIG. 1. 
Any organic or inorganic solvent may be used as long as 
both the polypeptide and polymer are soluble in the solvent 
and the solvent does not degrade or adversely affect the 
polymer or the polypeptide. 
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Suitable solvents include but are not limited to methylene 
chloride, hexa?uoroacetone, hexa?uoroisopropanol, 
acetonitrile, hexane, cyclohexane and the like. 
The preferred solvents are methylene chloride, hexa?uo 
roacetone and hexa?uoroisopropanol. 
A precipitate is thus obtained by forcing the polymer and 
protein/polypeptide out of the solution. The precipitation 
may be achieved by any technique knoWn in the art. Suitable 
techniques include adding a solvent in Which the polymer is 
not soluble or cooling the solution to achieve precipitation. 
The preferred precipitation technique involves forcing the 
polymer out of solution using a solvent in Which the protein/ 
polypeptide is soluble but in Which the polymer is not 
soluble. Suitable solvents include Water, aqueous buffer, 
aqueous-alcoholic mixtures and the like. Under the proper 
conditions of stirring, the particle siZe of the precipitate can 
be controlled. The precipitate is then ?ltered and dried. 
The precipitate includes both protein/-polypeptide and 
polymer and a physical interaction is present betWeen the 
protein/polypeptide and polymer. Controlled release of the 
protein/polypeptide in vivo is thereby achieved. 
If the microsphere technique is used as depicted in FIG. 
2, spherical polymer matrices or microspheres having a 
diameter range betWeen about 1 to 150 microns can be 
prepared in narroW siZe ranges for targeting to various organ 
or organ systems via parenteral injection or inhalation as 
shoWn in FIG. 4. A more preferred range for the spherical 
polymer matrices of microspheres is betWeen about 0.5 to 70 
microns. 
The microspheres may be prepared by forming emulsi?ed 
droplets or spheres consisting of a homogeneous mixture of 
polymer (or copolymer) and solvent from a solution of a 
preselected polymer dispersed in a continuous (non-solvent 
phase). Removal of the solvent from the sphere by any one 
or combination of (1) freeZe drying, or (2) solvent extraction 
creates the microsphere. The protein or polypeptide may 
then be added. 
In particular, in the microsphere method, the desired 
polymer or copolymer and the protein or polypeptide and 
other agents(s) are dissolved separately in a suitable solvent. 
The polymer and polypeptide solution are mixed together to 
provide a polymer concentration generally ranging betWeen 
about 2.5 to 18% W/W and a polypeptide/polymer ratio 
ranging betWeen about 1:1 to 1:100. The temperature of the 
resultant solution is generally controlled betWeen about 30° 
to 45° C. The polypeptide-polymer solution comprising the 
dispersed phase is dispersed into the continuous phase 
containing a surface active agent at a thermostatically con 
trolled temperature generally in the range of 10° to 20° C. 
Any surface active agent knoWn in the art Would be suitable 
in the practice of the present invention so long as it does not 
interfere With the activity or interaction betWeen the polymer 
and protein/polypeptide. The foregoing may be accom 
plished by any method knoWn in the art, in particular, by 
forcing the dispersed phase under pressure through a ?ne 
ori?ce noZZle. The continuous phase Which is 5 to 20 times 
by Weight of the dispersed phase is then agitated by a 
dispersator. FolloWing the introduction of the dispersed 
phase, one of tWo recovery methods is utiliZed to stabiliZe 
and recover the drug-loaded microspheres for ?nal process 
ing. 
More speci?cally, consistent With the freeZe-dry method, 
folloWing dispersion, the temperature is maintained at 10° to 
20° C., preferably 15° C., for tWo minutes then increased to 
45° to 55° C., preferably 50° C., over a three minute period. 
Vigorous agitation of the mixture is continued during this 
period. When the temperature reaches 50° C., either a 
US 6,306,406 B1 
refrigerant solution is circulated through the jacket from the 
bath or the container is immersed in dry ice-methanol and 
cooled to a temperature Which Will freeZe the drug-polymer 
solvent phase and not the continuous phase. The suspension 
or emulsion (solid dispersion phase in liquid continuous 
phase) is quickly transferred to precooled vials (—40° to 
—60° C.) and cooled to —40° to —60° C. in a freeZe dryer, 
freeZer or dry ice-acetone bath. The solvent in the suspended 
droplets (microspheres) and the continuous phase solvent 
are removed by freeZe drying. Upon completion of the 
freeZe dry cycle the microspheres are Washed With a suitable 
solvent, ?ltered and air dried. 
In the solvent extraction method of the invention, folloW 
ing dispersion, the temperature is maintained at 10° to 20° 
C., preferably 15° C., for tWo minutes, then increased to 45° 
to 55° C., preferably 50° C., over a three minute period. The 
dispersion is then transferred to a vessel containing a diluent 
solvent at room temperature or the diluent solvent is added 
to the dispersion. Agitation may be continued for approxi 
mately 30 minutes using an appropriate mixing technique. 
During the process the dispersed phase solvent is removed 
from the polypeptide-polymer-solvent emulsion droplets by 
extraction causing solidi?cation of the droplets. The solid 
spheres are then removed by ?ltration, Washed With a 
suitable solvent and air dried. 
Solvents for the dispersed phase and the continuous phase 
Will of course differ in order to attain phase separation and 
are, therefore, selected based upon the solvent requirements 
for each phase. More particularly, the solvent for the dis 
persed phase should preferably dissolve the polymer and the 
incorporated agent and remain in the emulsi?ed droplets 
With the drug and polymer in the continuous phase until 
leached out by a diluent solvent or removed by vaporization 
or evaporation. In this Way pores are optionally formed in 
the drug-polymer matrix. In the case of polyglycolic acid 
into Which Water soluble markers or agents are incorporated, 
hexa?uoroacetone sesquihydrate is an appropriate solvent. 
Other solvents Which can be used, depending upon the 
characteristics of the polymer and incorporated agents, 
include Water, hexa?uoro-isopropanol, methylene chloride, 
acetonitrile, tetrahydrofuran, hexane and benZene. Solvents 
for the continuous phase should not dissolve the polymer 
and should emulsify the dispersed phase. Suitable solvents 
include, but are not limited to, benZene, dioxane, acetone, 
methylene chloride, chloroform, carbon tetrachloride, 
toluene, ethyl alcohol, acetonitrile, p-xylene, 
tetrahydrofuran, mineral oil, glycerin and mixtures of these 
solvents. 
A diluent (non-solvent) phase can also be employed to 
dilute the continuous phase folloWing dispersion of the 
polymer polypeptide solution. The diluent should be mis 
cible With the continuous phase and dispersed phase solvents 
but not dissolve the polymer or incorporated agent. 
Examples of suitable solvents include 1,4-dioxane, 
cyclohexanone, acetone, ethanol, isopropanol, acetonitrile, 
dimethylformamide, tetrahydrofuran, cyclohexanol and the 
like. 
The concentration of polymer in the dispersed phase 
directly in?uences the porosity or “void” space in the ?nal 
microsphere product as Well as the shape of the microsphere. 
A concentration of 2.5% to 10% W/W polymer yields dimen 
sionally suitable spherical particles. With respect to the 
concentration of the protein or polypeptide, up to 50% by 
Weight of the polymer has been achieved With consistent 
results. 
It has been determined that certain processing parameters 
in?uence the recovery methods as Well as the resultant 
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microspheres of the present invention. Identi?able param 
eters include the concentration of polymer in the dispersed 
phase, the temperature of the dispersed phase at the time of 
dispersion, the concentration of surfactants in the dispersed 
phase as Well as the ratio of incorporated agent to polymer 
in the dispersed phase. It Will be appreciated that the 
concentrations, temperatures and ratios referred to herein 
above and in the Examples set forth operable ranges and that 
other numerical expressions may apply as different solvents, 
polymers, proteins, polypeptides and the like, are selected. 
The present inventor Wishes to emphasiZe that the inter 
action betWeen the protein/polypeptide and the polymer of 
the present invention is unique. In the prior art, there Was no 
af?nity betWeen the active drug substance and the polymer. 
In fact, in some instances, the af?nity of the drug Was much 
greater for the solvent in Which the polymer and drug Were 
dissolved. Thus, in the prior art systems, When the polymer 
Was precipitated from the solution, the drug remained pre 
dominantly in the solution. 
The drug delivery systems in accordance With the present 
invention are ideally suited for administration by the 
parenteral (e.g., intravenous, intraarterial, intramuscular, 
subcutaneous or intraocular) or inhalation routes of admin 
istration but can be used for oral and intranasal administra 
tion if such administration enhances bioavailability or 
reduces side effects. In particular, the macroparticulate sys 
tems in the proper siZe range, i.e., about 0.5 pm to about 5 
pm, can also be administered orally for adsorption and/or 
pinocytosis by the mucosal cells lining the gastrointestinal 
tract. Such administration permits transfer of the incorpo 
rated agent intact to the systemic, lymphatic and secretory 
systems of the body. 
It Will be appreciated by those skilled in the art that the 
drug delivery system of the present invention may be 
administered alone or in admixture With appropriate phar 
maceutical diluents, carriers, excipients or adjuvants suit 
ably selected With respect to the intended route of admin 
istration and conventional pharmaceutical practices. For 
example, for parenteral injection, dosage unit forms may be 
utiliZed to accomplish intravenous, intramuscular or subcu 
taneous administration, and for such parenteral 
administration, suitable sterile aqueous or non-aqueous solu 
tions or suspensions, optionally containing appropriate sol 
utes to effectuate isotonicity, Will be employed. LikeWise for 
inhalation dosage unit forms, for administration through the 
mucous membranes of the nose and throat or bronchio 
pulmonary tissues, suitable aerosol or spray inhalation com 
positions and devices Will be utiliZed. 
Consistent With other preferred embodiments of the 
present invention, the drug delivery system of the invention 
may be additionally coated or modi?ed to advantageously 
in?uence the targeting of the release of the incorporated drug 
therein to preselected target cells, tissues or organs. For 
example, the drug delivery microspheres may be coated With 
various agents, e.g., polymers, proteins, surfactants, anti 
bodies or receptor site speci?c drugs Which may be the same 
or different from those incorporated in the microsphere 
Whereby the release of the incorporated drug is concentrated 
at the targeted system. Additionally, the coatings can be pH 
sensitive so as to effect protection folloWing oral adminis 
tration and transit through the stomach. 
In order further to illustrate the present invention and the 
advantages thereof, the folloWing speci?c examples are 
given, it being understood that same are intended only as 
illustrative, not limitative. 
EXAMPLE 1 
Molecular Interaction of Salmon Calcitonin With 
Polyglycolic Acid 
The present example Was intended to quantify chemical 
and/or physical association betWeen salmon calcitonin and 
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polyglycolic acid (PGA) having a molecular Weight of 
40,000 Daltons. 
Approximately ?ve mg of calcitonin Were quantitatively 
Weighed and placed in each of a series of 5 ml volumetric 
?asks. Hexa?uoroacetone sesquihydrate (HFA) Was added 
dropWise until the calcitonin dissolved completely. A 5% 
PGA in HFA solution Was quantitatively added dropWise to 
each ?ask to provide a mass of PGA covering the range of 
0 to 26.3 mg. The ?asks Were agitated for 5 minutes to mix 
the solution. Each ?ask Was then ?lled to the 5 ml mark With 
phosphate buffer (pH 7.3). The addition of buffer precipi 
tated the PGA plus any calcitonin that had bound With the 
polymer. The resulting mixture Was centrifuged and the 
supernatant Was analyZed spectrophotometrically for salmon 
calcitonin content. 26 mg of PGA (40,000 MW) removed 
approximately 4.1 mg (83%) of salmon calcitonin. The 
results are set forth in Table I. 
TABLE I 
SUPER 
PGA NATANT CALCITONIN CALCITONIN % 
MASS ABS CONC. REMOVED CALCITONIN 
(mg) (275 nm) (mg/ml) (mg) REMOVED 
0.00 0.390 1.020 0.099 1.90 
5.73 0.342 0.895 0.125 2.71 
7.81 0.285 0.746 1.07 22.3 
7.89 0.356 0.932 0.340 6.80 
11.8 0.213 0.558 1.71 38.0 
13.2 0.257 0.673 1.64 32.7 
14.0 0.220 0.576 2.02 41.2 
15.8 0.176 0.461 2.69 53.7 
18.4 0.086 0.226 3.87 77.4 
10.4 0.165 0.432 2.54 54.0 
21.0 0.068 0.175 4.10 82.1 
22.3 0.161 0.422 2.95 58.6 
23.7 0.105 0.276 3.62 72.4 
26.3 0.066 0.174 4.13 82.6 
EXAMPLE 2 
Molecular Interaction of Salmon Calcitonin With 
Poly(Glycolic-Co-Lactic Acid) 
The procedure of preparing the poly(glycolic-Co-lactic 
acid) (PGL) having a molecular Weight of 50,000 micro 
spheres Was similar to that used for PGA, except the 
hexa?uoro-2-propanol Was substituted for HFA. Above 8 
mg of PGL over 80% of salmon calcitonin Was removed. 
The results are set forth in Table II. 
TABLE II 
SUPER 
PGA NATANT CALCITONIN CALCITONIN % 
MASS ABS CONC. REMOVED CALCITONIN 
(mg) (275 nm) (mg/ml) (mg) REMOVED 
0.00 0.360 0.941 0.591 11.1 
2.64 0.306 0.801 0.995 19.9 
4.13 0.210 0.550 2.15 43.9 
5.52 0.191 0.501 2.69 51.8 
6.51 0.147 0.386 2.87 59.8 
8.45 0.065 0.172 3.64 80.8 
11.53 0.047 0.125 4.37 87.5 
13.57 0.027 0.0725 4.44 92.5 
20.97 0.034 0.0908 4.95 91.6 
EXAMPLE 3 
Molecular Interaction of Salmon Calcitonin With 
Polylactic Acid 
The procedure for preparing the polylactic acid (PLA), 
dl-type having a molecular Weight of 50,000, Was similar to 
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that used for PGA, except that methylene chloride Was 
substituted for HFA and the calcitonin Was suspended rather 
than dissolved in the methylene chloride. In addition, since 
methylene chloride and buffer are not miscible, salmon 
calcitonin Was extracted from methylene chloride in buffer. 
The aqueous phase Was separated, centrifuged and the 
supernatant Was analyZed spectrophotometrically for salmon 
calcitonin. The results are set forth in Table III. 
TABLE III 
SUPER 
PGA NATANT CALCITONIN CALCITONIN % 
MASS ABS CONC. REMOVED CALCITONIN 
(mg) (275 nm) (mg/ml) (mg) REMOVED 
0.00 0.401 1.05 0.055 1.03 
2.68 0.226 0.592 2.04 40.8 
4.81 0.186 0.488 2.36 47.2 
10.28 0.147 0.386 2.77 55.4 
14.95 0.105 0.276 3.62 72.4 
20.40 0.159 0.417 3.02 60.3 
EXAMPLE 4 
Molecular Interaction of Salmon Calcitonin With 
Pure Polymer 
Approximately 100 mg of PGA (MW 40,000) Was placed 
in a vial. Ten ml of a 1 mg/ml calcitonin in phosphate buffer 
(pH 7.3) Were added to the vial. The polymer Was suspended 
in the calcitonin solution by placing the vial in an ultrasonic 
bath for 10 minutes. The suspension Was then centrifuged 
and the supernatant Was analyZed spectrophotometrically. 
This procedure Was repeated for PGA (MW 100,000), PGL 
and PLA (dl-type) polymers, With the revision that all 
quantitative amounts Were halved for the PGL and PLA 
trials. The results are set forth in Table IV. 
TABLE IV 
SUPER 
NATANT CALCITONIN mg SCT per 
MASS ABS REMOVED mg POLYMER 
POLYMER (mg) (275 nm) (mg) REMOVED 
PGA 99.1 0.4022 0.723 0.723/991 
(40,000) 
PGA 99.3 0.3501 1.143 1.143/993 
(100,000) 
PGL 50.0 0.4144 0.457 0.457/503 
(50,000) 50.0 0.2474 2.772 2.772/500 
PLA 
(dl-type) 
(50,000) 
The pure polymers shoWed a binding a?inity, up to 5.5%, 
Which Was less than the molecular interaction during the 
precipitation process. PLA (dl-type) shoWed the highest 
a?inity to bind With salmon calcitonin When suspended in a 
1 mg/ml solution. 
Since the PGA system Was the polymer of choice for 
preparing microspheres by the freeZe drying technique, 
some efforts Were made to determine the nature of the 
association betWeen drug and polymer. UtiliZing differential 
scanning calorimetry there Was some shifts in the melting 
points of salmon calcitonin and PGA When these agents 
Were combined in microspheres. Changes Were also 
observed in the IR. and Raman spectra. All of these suggest 
an association but do not conclusively point to the precise 
nature of the interaction. HoWever, Fourier Transfer Raman 
spectrometry did not shoW any discernible differences. This 
suggests that the interaction is not chemical or covalent in 
nature. 
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EXAMPLE 5 
Preparation of a Salmon Calcitonin-PGA 
Precipitated System 
1. Precipitation With Water 
49.3 mg of salmon calcitonin Was placed in a vial and 
dissolved With 0.35 ml HFA sesquihydrate. A4.5 g of a 10% 
PGA-HFA solution containing 450 mg of PGA Was added 
dropWise to the solution While stirring With a magnetic 
stirring bar. The mixture Was agitated for 5 additional 
minutes. A pH 7.3 phosphate buffer Was then added to the 
mixture to precipitate the polymer. Turbidity suggested the 
precipitation of the polymer. The mixture Was agitated tWo 
more minutes using a vortex mixer and then centrifuged for 
10 minutes at 3000 rpm. The supernatant Was saved for 
analysis and the precipitate dried in a loW pressure chamber 
for a feW hours. The salmon calcitonin of the content of the 
supernatant Was analyZed spectrophotometrically and the 
amount of the active agent removed by the polymer Was 
calculated. Loading Was betWeen 6.0 to 8.0% by Weight of 
polymer. 
2. Precipitation With Ethyl Alcohol 
The buffer Was replaced by ethanol to precipitate the 
polymer to attempt to improve the yield. The total solid input 
(polymer+salmon calcitonin) Was 502 mg in this prepara 
tion. A loading of 6.4 to 8.0% Was used. 
EXAMPLE 6 
Characterization of Salmon Calcitonin-PGA 
Microspheres and Precipitate 
1. Blank Microspheres 
a) Drug Load 
Microspheres Were prepared as described in Example 5 
using 100,000 molecular Weight polyglycolic acid. Because 
of the association tendency of salmon calcitonin With polyg 
lycolic acid, it Was not possible to use the precipitation 
technique to determine actual drug load. The 30 minute 
extraction technique in buffer Was more indicative of actual 
salmon calcitonin content. By the extraction method and 
HPLC analysis, a drug content of 8.21 % W/W Was calculated 
as 82% incorporation efficiency. 
b) In Vitro Release of Salmon Calcitonin 
TWenty mg of PGA-salmon calcitonin microspheres Were 
loaded into a test tube. Ten ml of a 0.1M phosphate buffer, 
pH 7.4, containing EDTA Were added and the tubes trans 
ferred to a 37° C. Water bath. Results of this study are shoWn 
in FIG. 5. Nineteen pg salmon calcitonin/mg microspheres 
Were released initially as a burst. This initial release Was 
folloWed by a fast release of 50% of the total drug in less 
than tWo hours. At this point, a sloW release folloWed and 22 
pg salmon calcitonin/mg microspheres (22% of total drug) 
Was released in the folloWing 29 hours. The data from this 
study suggested that salmon calcitonin remains stable in the 
phosphate buffer for about 35 hours. 
2. Precipitate 
a) SiZe Distribution 
HIAC/ROYCO counter-siZe analyZer Was used to analyZe 
the drug loaded precipitate for siZe distribution. As shoWn in 
FIG. 2, D50, the number median diameter, Was approxi 
mately 2.8 pm and 99% of the particles Were in the range of 
2—10 pm. The geometric standard deviation, og=1.83 is 
indicative of a fair monodispersity. MMD, mass median 
diameter, Was calculated to be 4.39 pm. 
b) In Vitro Release of Salmon Calcitonin from Precipitate 
TWo 18 mg samples of salmon calcitonin-PGAprecipitate 
Were quantitatively transferred to test tubes. Ten ml of a 
0.1M phosphate buffer, pH 7.4, containing EDTA Were 
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added to the samples and placed in a 37° C. shaker bath. 
Samples Were WithdraWn at predetermined time intervals 
and analyZed for drug content. As shoWn in FIG. 6, the initial 
release Was rapid. A release of 22% occurred at Zero time, 
folloWed by another 21% of the total drug released in less 
than 2 hours. This Was folloWed With only negligible release 
for the next 30 hours of about 0.1% per hour. A signi?cant 
amount of salmon calcitonin appears to be still Within the 
matrix or bound to the polymer. 
EXAMPLE 7 
In Vivo Assessment of Salmon Calcitonin 
Sustained Release From Biodegradable 
Microspheres 
Biodegradable microspheres containing salmon calcito 
nin Were prepared With polyglycolic acid, 40,000D by a 
freeZe-drying technique as depicated in FIG. 2. Salmon 
calcitonin microspheres With different salmon calcitonin 
contents Were characteriZed for particle siZe, porosity, spe 
ci?c surface area and in- vitro release. The sustained hypoc 
alcemic effect Was assessed by subcutaneous injection in 
male Wistar rats, folloWed by blood sampling via femoral 
artery catheter at de?ned time intervals and assaying for 
serum calcium concentrations. Drug loads of 0.3, 4.5 and 
7.5% Were evaluated and a level of 0.3% Was found to be 
effective in producing a sustained hypocalcemic effect. With 
this drug load, salmon calcitonin microspheres containing 
40, 120 and 360 mU of salmon calcitonin per 100 g body 
Weight Were administered as illustrated in FIG. 7. The 
hypocalcemic effect Was sustained for a 24 hour period With 
the salmon calcitonin microspheres as compared to 2 to 3 
hours With free salmon calcitonin. Additionally, salmon 
calcitonin blood levels Were sustained at concentrations 
higher than baseline for a period of ?ve days. 
From the foregoing description, one of ordinary skill in 
the art can easily ascertain the essential characteristics of the 
instant invention, and Without departing from the spirit and 
scope thereof, can make various changes and/or modi?ca 
tions of the invention to adapt it to various usages and 
conditions. As such, these changes and/or modi?cations are 
properly, equitably and intended to be Within the full range 
of equivalence of the folloWing claims. 
What is claimed is: 
1. A drug delivery system for controlled release of 
calcitonin, said delivery system comprising a biodegradable 
hydrophobic polymer selected from the group consisting of 
polyglycolic acid, polylactic acid, copolymers of glycolic 
acid and L- or D,L-lactic acid, and copolymers of glycolide 
and L- or D,L-lactide; and calcitonin, Wherein calcitonin is 
adsorbed to the polymer and a hydrophobic bond is present 
betWeen said polymer and calcitonin Whereby protection and 
controlled release of calcitonin is achieved in vivo. 
2. A process for preparing a drug delivery system for 
controlled release of calcitonin, said process comprising: 
(a) dissolving calcitonin and a hydrophobic biodegradable 
polymer selected from the group consisting of polyg 
lycolic acid, polylactic acid, copolymers of glycolic 
acid and L- or D,L-lactic acid, and copolymers of 
glycolide and L- or D,L-lactide, in a ?rst solvent and 
dispersing the solution in a second solvent to form 
microdroplets, 
(b) extracting the ?rst solvent from the microdroplets, 
such that an interaction occurs at the aqueous polymer 
interface causing the calcitonin to adsorb to the 
polymer, and hardening the polymer such that 
calcitonin-loaded microspheres are formed. 
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3. A process for preparing a drug delivery system for 
controlled release of calcitonin, said process comprising: 
(a) dissolving calcitonin and a hydrophobic biodegradable 
polymer selected from the group consisting of polyg 
lycolic acid, polylactic acid, copolymers of glycolic 
acid and L- or D,L-lactic acid, and copolymers of 
glycolide and L- or D,L-lactide, in a ?rst solvent, and 
(b) adding a second solvent in Which calcitonin is soluble, 
causing the polymer to precipitate and form micropar 
ticles to Which calcitonin is adsorbed. 
4. The process as claimed in claim 2, Wherein the micro 
spheres are reduced in siZe. 
5. The process as claimed in claim 3, Wherein the micro 
particles are reduced in siZe. 
6. A process as claimed in claim 3 Wherein said second 
solvent is selected from the group consisting of Water, 
aqueous buffer and aqueous-alcoholic mixture. 
7. A process for preparing a drug delivery system for 
controlled release of calcitonin, said process comprising: 
a) dissolving calcitonin and a hydrophobic biodegradable 
polymer selected from the group consisting of polyg 
lycolic acid, polylactic acid, copolymers of glycolic 
acid and L- or D,L-lactic acid, and copolymers of 
glycolide and L- or D,L-lactide, in a ?rst solvent to 
form a ?rst phase; 
b) dispersing said ?rst phase in a continuous second 
solvent phase to obtain a suspension, and 
c) removing said ?rst and second solvents from said 
suspension by freeZe-drying to obtain microspheres 
containing the calcitonin and polymer. 
8. The process as claimed in claim 7, Wherein the micro 
spheres are reduced in siZe. 
9. A drug delivery system for controlled release of calci 
tonin prepared according to the process of claim 2. 
10. A drug delivery system for controlled release 
calcitonin prepared according to the process of claim 3. 
11. A drug delivery system for controlled release 
calcitonin prepared according to the process of claim 7. 
12. A drug delivery system for controlled release of 
calcitonin, said delivery system comprising a biodegradable 
hydrophobic polymer selected from the group consistion of 
polyglycolie acid, polylactic acid, copolymers of glycolic 
acid and L- or D,L-lactic acid, and copolymers of glycolide 
and L- or D,L-lactide; and calcitonin, Wherein calcitonin is 
adsorbed to the polymer and a hydrophobic bond is present 
betWeen said polymer and calcitonin, and not a covalent 
bond or hydrogen bond as determined by differential scan 
ning calorimetry, infrared spectroscopy, Fourier transform 
of 
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infrared spectroscopy, Raman spectroscopy and Fourier 
transform Raman spectroscopy, Whereby protection and 
controlled release of calcitonin is achieved in vivo. 
13. A process for preparing a drug delivery system for 
controlled release of calcitonin, said process comprising: 
(a) dissolving calcitonin and a hydrophobic biodegradable 
polymer selected from the group consisting of polyg 
lycolic acid, polylactic acid, copolymers of glycolic 
acid and L- or D,L-lactic acid, and copolymers of 
glycolide and L- or D,L-lactide, in a ?rst solvent and 
dispersing the solution in a second solvent to form 
microdroplets, 
(b) extracting the ?rst solvent from the microdroplets, 
such that an interaction occurs at the aqueous polymer 
interface causing the calcitonin to adsorb to the poly 
mer and form a hydrophobic bond, and hardening the 
polymer such that calcitonin-loaded microspheres are 
formed. 
14. A process for preparing a drug delivery system for 
controlled release of calcitonin, said process comprising: 
(a) dissolving calcitonin and a hydrophobic biodegradable 
polymer selected from the group consisting of polyg 
lycolic acid, polylactic acid, copolymers of glycolic 
acid and L- or D,L-lactic acid, and copolymers of 
glycolide and L- or D,L-lactide, in a ?rst solvent, and 
(b) adding a second solvent in Which calcitonin is soluble, 
causing the polymer to precipitate and form micropar 
ticles to Which calcitonin is adsorbed, Wherein a hydro 
phobic bond is present betWeen said polymer and 
calcitonin. 
15. A process for preparing a drug delivery system for 
controlled release of calcitonin, said process comprising: 
a) dissolving calcitonin and a hydrophobic biodegradable 
polymer selected from the group consisting of polyg 
lycolic acid, polylactic acid, copolymers of glycolic 
acid and L- or D,L-lactic acid, and copolymers of 
glycolide and L- or D,L-lactide, in a ?rst solvent to 
form a ?rst phase; 
b) dispersing said ?rst phase in a continuous second 
solvent phase to obtain a suspension, and 
c) removing said ?rst and second solvents from said 
suspension by freeZe-drying to obtain microspheres 
containing the calcitonin and polymer, Wherein calci 
tonin is adsorbed to the polymer and a hydrophobic 
bond is present betWeen said polymer and calcitonin. 
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